Connect
← Return to Treatment for Prostate Cancer Metastasized to Bones
Discussion
Treatment for Prostate Cancer Metastasized to Bones
Prostate Cancer | Last Active: Feb 27 7:27am | Replies (146)Comment receiving replies
Thanks for sharing this.
That's definitely a encouraging clinical trial, assuming the results are comparable, which I am unqualified to assess. If I understand correctly, from whatever the starting point was, the mean overall survival rate was 40 months for the standard of care treatment, and increased by over 20% to 52.2 months with the treatment plan undergoing the clinical trial. Yeah!
Also, great news that at 26 mos from this diagnosis you have no (noticeable) progression. That sounds great to me.
Note: I'm not sure if the other study starting point was newly diagnosed bone-metastatic prostate cancer either. I tried to note that in my comments, but I don't know if it came across. Since I am not a researcher in this field, I am really unqualified to make any independent assessment of these articles. When I summarize something, I'm just restating what [I think] I am reading.
With regard to the link you posted, I only got access to the abstract there. Perhaps the article itself is behind a paywall?
In any case, I have no idea what the actual situation is, but I certainly like 52 months better than a lower number for overall survival :-). Thanks for posting this. Since this was a phase 3 trial over 2 years ago and it went well, can I assume this is now a publicly available treatment option?!
Replies to "Thanks for sharing this. That's definitely a encouraging clinical trial, assuming the results are comparable, which..."
Connect
Thank you for your reply. Coincidentally, this morning my spouse was just going over her notes from the first few weeks after my diagnosis and surgery, when I was in a pretty bad place. The oncology team at our Cancer Centre told her that in a case like mine (single metastasis to the spine, though a big enough one to leave me temporarily paraplegic), I could expect 5 to 10 years before organ involvement, and even that might also be easily treatable depending on where the cancer moved. I assume that estimate was based on ADT alone, because we don't have 10 years of data for androgen-receptor inhibitors like Erleada yet, but it might also be an educated guess taking Erleada into account.